Bruce R. Rowley
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Monoclonal and Polyclonal Antibodies Research, T-cell and B-cell Immunology, Lung Cancer Treatments and Mutations, Cancer-related Molecular Pathways
Most-Cited Works
- → BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis(2004)4,005 cited
- → Syk tyrosine kinase required for mouse viability and B-cell development(1995)626 cited
- → BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models(2013)254 cited
- → Tumor Development by Transgenic Expression of a Constitutively Active Insulin-Like Growth Factor I Receptor(2005)203 cited
- → Murine pregnancy decidua produces a unique immunosuppressive molecule related to transforming growth factor beta-2.(1990)154 cited
- → Disruption of epithelial gamma delta T cell repertoires by mutation of the Syk tyrosine kinase.(1996)74 cited
- → Constitutively active receptor tyrosine kinases as oncogenes in preclinical models for cancer therapeutics(2006)6 cited
- → Abstract 4476: BAY 80-6946, a highly selective and potent pan class I PI3K inhibitor induces tumor apoptosis in vitro and tumor regression in vivo in a sub-set of tumor models(2010)3 cited
- → Erratum: Syk tyrosine kinase required for mouse viability and B-cell development(1996)2 cited
- → Abstract C18: Assessment of Gli1 expression during skin regeneration in mouse models and normal healthy volunteers(2009)1 cited